In the preclinical development stage, Accelera is able to offer an integrated battery of profiling assays, including In-Vitro ADME and Tox called Attrition Reducing Technologies (ART), designed to accelerate the lead optimisation phase through several drug screening tests. ART allows sponsors to identify the most promising drug candidates at an early stage, while at the same time de-prioritise those with a high risk of failure during the development phase.
- Solubility and Partitioning
- Permeability and Transport
- Chemical stability
- Drug metabolism: metabolic stability, metabolite profiling and identification
- Drug-Drug Interaction
- PK/PD and PBPK.
A consolidated analytical platform, LC-MS-MS based, is applied in preclinical discovery for testing characteristics of potential new drugs.For more detailed information, request a copy of Accelera's ART catalogue.